News and Press Releases
Novo Nordisk A/S: Ozempic receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities
Pending a decision from the European Commission, Ozempic (once-weekly semaglutide) will have the broadest approved label in the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class, demonstrating improvements in blood sugar,...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: June 23, 2025
EuroPCR 2025: Late-Breaking Data Demonstrate Sustained Significantly Lower Event Rates With Elixir Medical’s DynamX Bioadaptor Over Drug-Eluting Stent Through Three Years
Sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) with DynamX compared to DES Significantly lower rate of Cardiac Death (0.5% versus 3.2%, p=0.033) with...
Category: Biotechnology, Clinical Trials, Other
Posted: May 21, 2025
Clean Cells acquires Karyologic to accelerate expansionin US biologics market
8 April 2025 -- Montaigu-Vendée, near Nantes, France -- Clean Cells, part of the Clean Biologics group, a leading biopharmaceutical quality control services provider specializing in biologics GMP testing, today...
Category: BioManufacturing, Other, Pharmaceutical
Posted: April 8, 2025
4 Rue Nicolas Sadi Carnot ZA le Point du Jour 85600 MONTAIGU – VENDÉE FRANC
Epsilogen Announces Acquisition of TigaTx, Inc. to Create World’s Leading Pan-Isotype Cancer Antibody Company
The acquisition combines IgA antibody assets and expertise of Boston-based TigaTx with Epsilogen’s assets and expertise in IgE to create the world’s leading pan-isotype cancer antibody company Allows selection of...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 7, 2025
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Rybelsus reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial Data were...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 29, 2025
Cleerly to Present Late-Breaking Clinical Trial Results on Cardiovascular Risk in Women at ACC 25
Cleerly to Present Late-Breaking Findings and Participate in Key ACC 25 Sessions 27 March 2025 -- Illinois, US -- Cleerly, the leader in cardiovascular AI imaging, announces its participation in...
Category: Clinical Trials, Other, Pharmaceutical
Posted: March 27, 2025
Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer
24 March 2025 -- California, US and Suzhou, China -- Innovent Biologics, Inc, a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology,...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 24, 2025
Venus Remedies gets Marketing Authorization for anticoagulant ‘Enoxaparin’ from Indonesia
Latest approvals from Indonesia, Southeast Asia’s largest pharma market, to help strengthen company’s regional and global aspirations 10 February 2025 -- Panchkula, India -- Venus Remedies Limited, a leading Indian exporter...
Category: Drug Delivery, Other, Pharmaceutical
Posted: February 10, 2025
51-52, Industrial Area Phase-1, Panchkula, Haryana, 134113
Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds
7 February 2025 -- Bagsværd, Denmark -- Novo Nordisk today announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia A with...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 7, 2025
Novo Nordisk to present new data from sickle cell disease and haemophilia trials at the 66th American Society of Hematology (ASH) annual meeting
HIBISCUS phase 2 data evaluating the safety profile and efficacy of etavopivat in adult and adolescent patients with sickle cell disease FRONTIER4 interim phase 3 results evaluating safety profile and...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 3, 2024
Swixx Biopharma Expands to Latin America Through a Strategic Acquisition and Combination with Biopas
With the addition of $220m in sales, over 300 employees and therapeutic coverage in Neurology, Oncology, Immunology, Gastroenterology, Rare Diseases and Specialty, acquisition extends and transforms Swixx BioPharma’s footprint The...
Category: Other, Pharmaceutical
Posted: May 22, 2024
Myonex Closes Creapharm Acquisition Expanding Global Services
2 May 2024 -- Pennsylvania, US -- Myonex has completed the previously announced acquisition of Creapharm’s pharmaceutical services business. This transaction combines capabilities and flexibility to serve pharmaceutical and biotech...
Category: Biotechnology, Pharmaceutical
Posted: May 2, 2024
Myonex Announces Acquisition of Safeway Compounding Pharmacy to Expand its Clinical Trial Services Across the US
9 April 2024 -- Horsham, US -- Myonex, a leading global clinical trial supply company, has completed the acquisition of SaveWay Compounding Pharmacy of Newark, US. The pharmacy will operate as...
Category: Clinical Trials
Posted: April 9, 2024
Bora Pharmaceuticals completes the acquisition of Upsher-Smith
Acquisition expands Bora’s North American footprint with first US manufacturing site 1 April 2024 -- Taipei, Taiwan -- Bora Pharmaceuticals today announced that it has completed the acquisition of Upsher-Smith Laboratories,...
Category: BioManufacturing
Posted: April 1, 2024
6F., No. 2, Aly. 36, Ln. 26, Ruiguang Rd., Neihu District, Taipei City, 114 Taiwan
Indegene acquires Trilogy Writing & Consulting GmbH, a medical writing consultancy
27 March 2024 -- Princeton, US, and Frankfurt, Germany -- Indegene, a digital-first, life sciences commercialisation company, announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy), a global provider...
Category: Pharmaceutical
Posted: March 27, 2024
